WebMARLBOROUGH, Mass., June 16, 2024 /PRNewswire/ — CardioFocus, Inc., today announced that the first U.S. patients have been treated commercially with the recently-approved HeartLight X3 Endoscopic Ablation System. The revolutionary cardiac ablation technology is designed to treat drug refractory, symptomatic paroxysmal atrial fibrillation … Web12 de may. de 2024 · “FDA approval of the HeartLight X3 system represents a substantial milestone for CardioFocus and is a promising new treatment option for the millions of Americans suffering from paroxysmal AFib,”...

Russell Johnson, B.S.E.E. - Manager, Regulatory Affairs

Web12 de may. de 2024 · “FDA approval of the HeartLight X3 system represents a substantial milestone for CardioFocus and is a promising new treatment option for the millions of … Web12 de may. de 2024 · Approval of the HeartLight X3 System came as a result of a comprehensive submission, including outcomes from the study of 60 HeartLight X3 … gtwn4250d2ws parts

Irregular heartbeat treatment - HeartLight by CardioFocus (3D

WebMore than 33 million patients worldwide suffer from AFib, the most common type of cardiac rhythm disorder.1 The HeartLight X3 System is a third generation AFib ablation technology, building upon the advanced features of the HeartLight Endoscopic Ablation System, which performs PVI using laser energy to create lines of scar tissue to block the … Web6 de oct. de 2024 · The HeartLight X3 System is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation. The HeartLight X3 System … Web23 de jun. de 2024 · The HeartLight X3 System is a revolutionary catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for AFib. Using direct tissue... gtwn4250d1ws parts